Ascletis Pharma of Hangzhou reported that Zhejiang Province authorities approved a trial of ritonavir in patients with COVID-19. Ritonavir is a generic version of AbbVie’s Norvir, an oral antiretroviral that has been in use for over 20 years to treat HIV/AIDS. The study is being run jointly by Ascletis and the First Affiliated Hospital of Zhejiang University School of Medicine. According to Ascletis, it is currently conducting four clinical trials that combine ritonavir and ASC09, a protease inhibitor that is also being tested as an HIV treatment. More details....
Stock Symbol: (HK:1672)
Share this with colleagues: